Sexually Transmitted Diseases Drug

Sexually Transmitted Diseases Drug Market Outlook

The global sexually transmitted diseases (STD) drug market was valued at approximately USD 20 billion in 2023 and is projected to reach around USD 25 billion by 2035, growing at a CAGR of about 4% during the forecast period. This market growth can be attributed to several factors, including the increasing prevalence of STDs worldwide, rising awareness and education regarding sexual health, and the ongoing development of new and more effective therapeutic options. Additionally, the growing usage of telemedicine and the expansion of online pharmacies have made it easier for patients to access treatment, further driving market growth. The focus on comprehensive sexual health programs and public health campaigns aimed at reducing the incidence of STDs is expected to contribute significantly to the market's positive trajectory. The ongoing research and development initiatives aimed at creating innovative drug formulations and delivery systems will also play a crucial role in sustaining the momentum of the STD drug market.

Growth Factor of the Market

The growth of the sexually transmitted diseases drug market is driven by a plethora of factors, among which the rising incidence of STDs stands out prominently. The World Health Organization has reported a significant increase in infections such as chlamydia, gonorrhea, and syphilis, resulting in heightened demand for effective treatment options. Additionally, increased awareness and advocacy for sexual health education, especially among younger populations, are fostering greater acceptance of testing and treatment for STDs. This educational push is essential as it aids in breaking down the stigma associated with these diseases, encouraging more individuals to seek medical help. Furthermore, advancements in pharmaceutical research have led to the development of novel drugs that are more effective, have fewer side effects, and are easier to administer. As public health initiatives continue to focus on reducing the transmission of STDs through prevention and treatment strategies, the market is set to flourish, creating a conducive environment for investment and innovation within this sector.

Key Highlights of the Market

• The global STD drug market is expected to grow at a CAGR of 4% from 2023 to 2035.
• Antibiotics are the leading drug type segment due to their effectiveness against bacterial STDs.
• Online pharmacies are gaining traction as a preferred distribution channel due to convenience.
• Chlamydia and gonorrhea remain the most prevalent diseases driving market demand.
• North America holds the largest market share owing to advanced healthcare infrastructure and high awareness levels.

By Drug Type

Antibiotics:

Antibiotics represent the largest segment within the sexually transmitted diseases drug market, predominantly due to their essential role in treating bacterial infections such as chlamydia, gonorrhea, and syphilis. These medications work by targeting and eliminating bacteria, effectively curing the infection when taken as prescribed. The rise in antibiotic-resistant strains of bacteria has prompted extensive research into new formulations and combinations of existing drugs, which has further fueled innovation in this segment. Moreover, public health campaigns aimed at increasing testing and treatment for bacterial STDs have positively impacted the demand for antibiotics. As healthcare professionals aim to provide effective and prompt treatment options, the antibiotic segment is expected to continue its dominance in the market over the forecast period.

Antivirals:

The antivirals segment has been gaining significance in the STD drug market, primarily due to the increasing prevalence of viral infections, particularly HIV and herpes simplex virus. Antiviral medications are crucial for managing these infections, helping to reduce viral load and transmission rates among infected individuals. Innovations in antiviral therapies have led to the development of drugs that not only improve the quality of life for patients but also enhance adherence to treatment regimens. The ongoing research into long-acting injectable formulations is further expected to spur growth in this segment, making it easier for patients to maintain effective viral suppression without the need for daily pill intake. Consequently, the antiviral drug segment is projected to witness substantial growth as awareness and treatment options continue to expand.

Antifungals:

Antifungal drugs are essential for treating sexually transmitted fungal infections, such as candidiasis, which is notably common among various demographics. The effectiveness of antifungals in treating these infections has led to a steady demand for this category, particularly in regions where such infections are prevalent. With the rise of over-the-counter antifungal treatments, coupled with increasing public awareness about fungal STDs, the antifungal segment is witnessing robust growth. Additionally, the ongoing research aimed at developing novel antifungal agents that can minimize side effects and improve efficacy is expected to further bolster this market segment. As healthcare providers increasingly recognize the importance of addressing fungal infections in the context of sexual health, the antifungal segment is anticipated to continue expanding in the coming years.

Antiparasitics:

The antiparasitic drug segment addresses infections caused by parasitic organisms, such as trichomoniasis, which can significantly affect sexual health. This segment has been gaining attention as awareness grows regarding the role of parasites in STDs. Antiparasitic drugs are effective in treating these infections and play a critical role in managing symptoms and preventing complications. The increasing focus on preventive healthcare measures, including routine screening for STDs, is expected to drive demand for antiparasitic treatments further. As more healthcare providers incorporate antiparasitic treatments into sexual health management programs, the segment is likely to witness significant growth, driven by both increasing infection rates and a greater emphasis on comprehensive treatment options.

Others:

The 'Others' category within the drug type segment encompasses a variety of therapeutic agents that do not fall neatly into the primary classifications of antibiotics, antivirals, antifungals, or antiparasitics. This segment may include adjunct therapies and newer investigational drugs that target various aspects of sexually transmitted diseases. As the landscape of STD treatment continues to evolve, emerging therapies in this category may gain traction, especially for complex or multi-drug resistant infections. The growing investment in research and development for novel therapeutic agents is anticipated to contribute positively to the growth of the 'Others' segment, diversifying treatment options and enhancing patient outcomes significantly.

By Route of Administration

Oral:

Oral administration remains one of the most common routes for delivering STD medications due to its convenience and ease of use. Patients prefer oral medications for their simplicity, as they can be taken at home without the need for medical supervision. This route is particularly prevalent for antibiotics and antiviral medications, which are often prescribed in pill form. The oral route facilitates adherence to treatment regimens, ensuring that patients complete their courses effectively. Moreover, the development of extended-release formulations is enhancing the effectiveness of oral medications by providing sustained drug levels in the bloodstream. As healthcare providers increasingly prioritize patient comfort and compliance, oral administration is expected to continue dominating the market in the years ahead.

Topical:

The topical route of administration is significant for treating certain sexually transmitted diseases, particularly those caused by viruses and fungi. Topical treatments are applied directly to the affected area, providing localized relief and minimizing systemic side effects. This route is commonly utilized for managing conditions like genital herpes and candidiasis, where localized application can effectively control symptoms. The growing preference for non-invasive treatment options among patients, combined with advancements in formulation technology that improves the absorption and efficacy of topical agents, is expected to drive the growth of this segment. As more patients seek discreet and effective treatment options, the topical administration route will likely see expanded adoption in the STD drug market.

Injectable:

Injectable medications are crucial in certain clinical settings, particularly for patients requiring rapid therapeutic action or long-acting treatments. This route is especially relevant for managing chronic viral infections such as HIV, where injectable antiretrovirals can provide sustained viral suppression. The development of long-acting injectable formulations is a game-changer, allowing patients to receive treatment less frequently while maintaining effective control over their infections. Moreover, the injectable route is beneficial for patients with adherence issues, as it minimizes the need for daily dosing. As healthcare providers continue to explore innovative delivery methods that enhance patient outcomes, the injectable segment is poised for growth, particularly in the context of chronic disease management.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a vital role in the distribution of STD medications, particularly for patients receiving inpatient or specialized care. These pharmacies are equipped to provide a comprehensive range of medications and offer valuable counseling services to ensure appropriate treatment regimens. Hospital pharmacies typically maintain a stock of both essential and specialized drugs, including those needed for complex cases or drug-resistant infections. Furthermore, the collaboration between healthcare professionals within hospital settings ensures that patients receive holistic care, integrating STD treatment into broader health management plans. As hospitals continue to emphasize integrated health services, the role of hospital pharmacies in distributing STD drugs will likely become increasingly important.

Retail Pharmacies:

Retail pharmacies comprise a significant distribution channel for sexually transmitted disease medications, providing convenient access to patients in the community. Patients often prefer retail pharmacies due to their accessibility and the ability to obtain medications without needing a prescription in some cases. The rise of pharmacy chains and independent stores offering a wide range of STD treatments has further fueled growth in this segment. Retail pharmacies also play a crucial role in educating patients about sexual health, encouraging testing, and promoting awareness of available treatments. As patients continue to seek convenient healthcare solutions, retail pharmacies are expected to remain key players in the distribution of STD medications.

Online Pharmacies:

Online pharmacies have emerged as a rapidly growing distribution channel in the sexually transmitted diseases drug market, offering patients unparalleled convenience and discretion. The shift towards e-commerce has been accelerated by increased internet access and the ongoing COVID-19 pandemic, which has emphasized the importance of remote healthcare solutions. Online pharmacies enable patients to obtain STD medications from the comfort of their homes, often providing additional resources such as telehealth consultations and educational materials. This accessibility is especially beneficial for those who may be hesitant to visit a healthcare provider in person due to stigma or privacy concerns. As regulations evolve and the number of reputable online pharmacies increases, this segment is projected to see significant growth, revolutionizing how patients access STD treatments.

By Disease Type

Chlamydia:

Chlamydia is one of the most commonly reported sexually transmitted diseases worldwide, driving a considerable portion of the STD drug market. The increasing incidence of chlamydia infections, especially among young adults, has created a high demand for effective treatment options. Antibiotics such as azithromycin and doxycycline are the standard treatment protocols, and their widespread availability has made it easier for healthcare providers to manage cases effectively. Ongoing public health initiatives aimed at increasing screening and awareness about chlamydia will continue to support the growth of this segment, as timely treatment is crucial in preventing complications and reducing transmission rates. Consequently, as the prevalence of chlamydia remains high, its drug segment is expected to sustain significant growth in the coming years.

Gonorrhea:

Gonorrhea is another prominent sexually transmitted infection that significantly impacts the STD drug market. The rise of antibiotic-resistant strains of Neisseria gonorrhoeae has heightened the urgency for effective treatment options, thereby spurring research into new therapies and treatment protocols. Current treatment guidelines recommend dual therapy with antibiotics to combat resistance, leading to an increased demand for specific medications. The severity of gonorrhea as a health concern, coupled with rising awareness and screening programs, will drive growth in this segment as healthcare providers work diligently to control its spread and improve patient outcomes. As the public health response to gonorrhea evolves, the market for its treatment will continue to expand.

Herpes:

Herpes simplex virus (HSV) infections represent a significant area of focus within the STD drug market, with antiviral drugs playing a critical role in managing symptoms and preventing outbreaks. Acyclovir and newer antiviral agents are commonly prescribed for controlling HSV infections, which can significantly improve patients' quality of life. The increasing prevalence of herpes infections and the ongoing education regarding the importance of treatment are driving demand for these medications. As society becomes more open about discussing and addressing sexual health issues, the market for herpes medications is set to grow, especially with the advent of innovative therapies that enhance treatment adherence and efficacy.

HIV/AIDS:

The HIV/AIDS segment is a cornerstone of the sexually transmitted diseases drug market, as the management of this chronic viral infection requires ongoing treatment with antiretroviral therapy. The introduction of long-acting injectable formulations has transformed the landscape of HIV treatment, providing patients with options that improve adherence and reduce the burden of daily medication. The increasing global prevalence of HIV, coupled with advancements in treatment modalities, continues to drive growth in this segment. Furthermore, awareness campaigns and improved access to healthcare services are pivotal in encouraging individuals to seek treatment. As the global focus shifts toward ending the HIV epidemic, the demand for effective therapies in this segment is expected to rise significantly.

Others:

The 'Others' disease type category includes various less prevalent sexually transmitted infections that still require effective treatment. These may encompass infections like syphilis, trichomoniasis, and HPV, among others. While the market for these diseases may not be as large as that for chlamydia or HIV, it remains vital to provide comprehensive care for all sexually transmitted infections. Growing awareness of the necessity for testing and treatment of these less common STDs is likely to influence the demand for medications in this category positively. As healthcare providers increasingly adopt holistic approaches to sexual health, the focus on treating diverse STDs will enhance the growth potential of this segment.

By Region

The regional analysis of the sexually transmitted diseases drug market reveals distinct differences in prevalence, access to treatment, and awareness levels. North America currently holds the largest share of the market, primarily due to its advanced healthcare infrastructure and the high prevalence of STDs. The estimated market size in North America is around USD 10 billion, with a projected CAGR of 5% over the forecast period, largely driven by increasing healthcare expenditure and ongoing public health initiatives aimed at reducing STD incidence. The availability of a wide range of treatment options and the focus on patient education contribute significantly to the region's dominance in the market.

In comparison, Europe represents a substantial segment of the STD drug market, with a valuation of approximately USD 7 billion. Similar to North America, European countries have implemented various public health campaigns and testing programs to address the growing incidence of STDs. However, the level of awareness and access to treatment may vary considerably across different countries within the region. The Asia Pacific region is also demonstrating remarkable growth potential, with anticipated market growth attributed to increasing awareness, rising infection rates, and expanding healthcare access. The market in Asia Pacific is projected to reach around USD 5 billion by 2035, reflecting a CAGR of 4% as urbanization and healthcare improvements continue to influence the landscape of sexual health.

Opportunities

The sexually transmitted diseases drug market presents numerous opportunities for growth and innovation. One of the primary opportunities lies in the increasing investment in research and development aimed at creating novel drug formulations and delivery systems. With the rise of drug-resistant infections, the need for innovative therapeutic options has never been more pressing. Pharmaceutical companies are focusing on developing combination therapies and long-acting formulations that can enhance adherence and patient outcomes. Moreover, the growing acceptance of telemedicine and online consultations is reshaping how patients access healthcare services. This shift not only enables broader access to medications but also encourages regular screening and treatment, contributing to better sexual health outcomes. Additionally, the potential for expanding preventive measures, including vaccines and pre-exposure prophylaxis (PrEP) for high-risk populations, presents a lucrative avenue for market players to explore.

Another significant opportunity lies in the rising global awareness surrounding sexual health and the destigmatization of STDs. Public health campaigns and educational initiatives are increasingly encouraging individuals to prioritize their sexual health and seek testing and treatment for STDs. This growing awareness is expected to lead to increased screenings, earlier diagnoses, and subsequently, higher demand for effective treatments. The expansion of online pharmacies and digital health platforms also plays a crucial role in enhancing accessibility to STD medications, particularly for individuals who may face barriers to traditional healthcare. As the emphasis on comprehensive sexual health care continues to gain traction, the STD drug market stands to benefit from new patient demographics seeking proactive health management.

Threats

While the sexually transmitted diseases drug market is poised for growth, several threats could impact its expansion. One major threat is the ongoing challenge of antimicrobial resistance, which poses significant risks in the treatment of bacterial STDs. The emergence of drug-resistant strains of pathogens can render standard treatment protocols ineffective, leading to increased morbidity and complicating efforts to control the spread of infections. This situation necessitates continuous investment in research and the development of new antibiotics and treatment strategies to address the growing resistance issue. Furthermore, fluctuations in healthcare regulations and reimbursement policies can create uncertainty in the market, affecting the accessibility of medications and potentially leading to increased out-of-pocket costs for patients.

Another critical concern is the persistent stigma associated with STDs, which can discourage individuals from seeking testing and treatment. Even as awareness campaigns work to educate the public, the stigma surrounding sexually transmitted infections remains a significant barrier to care. Patients may avoid seeking help due to fear of judgment or social repercussions, which can result in delayed diagnoses and treatment. Additionally, factors such as economic disparities and limited access to healthcare services in certain regions can exacerbate the problem, leaving vulnerable populations at a higher risk of untreated infections. Addressing these societal challenges will be crucial for the sustained growth and effectiveness of the STD drug market.

Competitor Outlook

• AbbVie Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Bristol-Myers Squibb Company
• Mylan N.V.
• Merck & Co., Inc.
• AstraZeneca plc
• Novartis AG
• Roche Holding AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Hoffmann-La Roche Ltd.
• Hetero Drugs Ltd.
• Ferring Pharmaceuticals Inc.

The competitive landscape of the sexually transmitted diseases drug market is characterized by a mix of established pharmaceutical giants and emerging companies focused on developing innovative therapies. Leading players such as AbbVie, Gilead Sciences, and Merck & Co. hold significant market shares, driven by their extensive portfolios of effective treatments and strong brand recognition. These companies invest heavily in research and development, ensuring that they remain at the forefront of therapeutic advancements and can respond to evolving public health needs. The competitive dynamics are further influenced by partnerships and collaborations among industry players, academic institutions, and government organizations aimed at accelerating drug discovery and improving access to treatment.

As the market matures, smaller companies and biotech firms are also emerging with specialized products tailored to niche segments within the STD drug market. These organizations often focus on developing targeted therapies or novel delivery methods that address specific patient needs. The entry of such firms is fostering innovation and encouraging larger companies to explore acquisitions and collaborations to enhance their product offerings. Additionally, regulatory considerations and market access challenges are shaping the competitive landscape, compelling companies to adapt their strategies to maintain compliance and successfully navigate complex approval processes.

Among the major companies, Gilead Sciences stands out for its extensive work in developing antiviral therapies, particularly for HIV/AIDS, while AbbVie is recognized for its strong portfolio of antibiotic treatments for bacterial STDs. Johnson & Johnson is also notable for its commitment to improving sexual health through innovative research and public health initiatives. The continued focus on patient-centered care, along with ongoing advancements in drug development, is likely to shape the competitive strategies of market players, ensuring that they remain responsive to the evolving landscape of sexually transmitted diseases.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Hetero Drugs Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hoffmann-La Roche Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ferring Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Sexually Transmitted Diseases Drug Market, By Drug Type
    • 6.1.1 Antibiotics
    • 6.1.2 Antivirals
    • 6.1.3 Antifungals
    • 6.1.4 Antiparasitics
    • 6.1.5 Others
  • 6.2 Sexually Transmitted Diseases Drug Market, By Disease Type
    • 6.2.1 Chlamydia
    • 6.2.2 Gonorrhea
    • 6.2.3 Herpes
    • 6.2.4 HIV/AIDS
    • 6.2.5 Others
  • 6.3 Sexually Transmitted Diseases Drug Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Sexually Transmitted Diseases Drug Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Topical
    • 6.4.3 Injectable

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Sexually Transmitted Diseases Drug Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Sexually Transmitted Diseases Drug market is categorized based on

By Drug Type

• Antibiotics
• Antivirals
• Antifungals
• Antiparasitics
• Others

By Route of Administration

• Oral
• Topical
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Disease Type

• Chlamydia
• Gonorrhea
• Herpes
• HIV/AIDS
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Bristol-Myers Squibb Company
• Mylan N.V.
• Merck & Co., Inc.
• AstraZeneca plc
• Novartis AG
• Roche Holding AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Hoffmann-La Roche Ltd.
• Hetero Drugs Ltd.
• Ferring Pharmaceuticals Inc.